Darolutamide has demonstrated good efficacy and QoL in this patient population and may offer one avenue to shorten the unmet need in nmCRPC.

The 2020 Gastrointestinal (GI) Cancers Symposium presented the latest data in the field, including findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

The authors of the study, published in Nature Immunology, have said that this offers “exciting opportunities for pan-cancer, pan-population” immunotherapies not previously thought possible.

Highly anticipated data from the Dutch-Belgian lung cancer screening trial, NELSON, has been published in the New England Journal of Medicine.